Related Experiment Video
Updated: Jun 28, 2025
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
Epistaxis Rates and Health Care Utilization in Patients With a Ventricular Assist Device
Eric Rohe1, Sarah Schmoker1, Kaeli Samson2
1Department of Otolaryngology Head and Neck Surgery, College of Medicine University of Nebraska Medical Center Nebraska Nebraska USA.
Objective:
Identify baseline epistaxis rates and epistaxis-related health care utilization trends in the ventricular assist device (VAD) population.
Methods:
Single center, retrospective cohort study consisting of chart review of adult VAD patients. Analysis of descriptive statistics was assessed using χ 2 tests, independent sample t tests, or Fisher's exact when expected counts were low. Logistic regression was used to assess associations between epistaxis and variables of interest.
Results:
Two hundred ninety patients were included in the analysis. Ninety-eight (33.8%) patients developed epistaxis and 84 (29.0%) received medical attention. Patients with gastrointestinal (GI) bleeding had increased rates of epistaxis (42.4% vs 29.0%). Logistic regression analysis found GI bleeding to have an adjusted odds of developing epistaxis of 1.94 (95% confidence interval [CI]: 1.12-3.37) and kidney disease to have an adjusted odds of 1.83 (95% CI: 1.06, 3.13).
Discussion:
VAD implantation improves survival and quality of life but also carries significant bleeding risks. At our institution, 29% of VAD patients received medical attention for epistaxis. GI bleeding and kidney disease were found to have increased adjusted odds of developing epistaxis. Fifty-nine percent of epistaxis events occurred while inpatient and 32.8% of events were seen in the emergency department.
Implications For Practice:
VAD patients are an at-risk group that could potentially benefit from preventative nasal hydration regimen.
